WHAT IS NEW?
Year : 2014 | Volume
: 5 | Issue : 2 | Page : 195--199
Perampanel: New drug for treatment of refractory partial onset seizures
Santosh Kumar Singh, Dick B. S. Brashier
Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India
Correspondence Address:
Santosh Kumar Singh
Department of Pharmacology, Armed Forces Medical College, Sholapur Road, Pune - 411 040, Maharashtra
India
Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest antiepileptic drugs for treatment of refractory partial onset seizures. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increase in intracellular Ca 2+ and selectively blocks AMPA receptor-mediated synaptic transmission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy.
How to cite this article:
Singh SK, Brashier DB. Perampanel: New drug for treatment of refractory partial onset seizures.Muller J Med Sci Res 2014;5:195-199
|
How to cite this URL:
Singh SK, Brashier DB. Perampanel: New drug for treatment of refractory partial onset seizures. Muller J Med Sci Res [serial online] 2014 [cited 2022 Aug 18 ];5:195-199
Available from: https://www.mjmsr.net/article.asp?issn=0975-9727;year=2014;volume=5;issue=2;spage=195;epage=199;aulast=Singh;type=0 |
|
|
|
